Qrativ

Cambridge, United States Founded: 2017 • Age: 9 yrs
AI based drug purposing platform to identify treatments for rare diseases
Request Access
Report Incorrect Data
Annual revenue - Latest available
Total funding $8.3M 1 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About Qrativ

Qrativ is a company based in Cambridge (United States) founded in 2017 by Murali Aravamudan and Andrew Badley. Qrativ has raised $8.3 million across 1 funding round from investors including Matrix. Qrativ operates in a competitive market with competitors including Causaly, ScienceIO, Collaborative Drug Discovery, BioSymetrics and Citelighter, among others.

  • Headquarter Cambridge, United States
  • Founders Murali Aravamudan, Andrew Badley
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research → →
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $8.3 M (USD)

    in 1 rounds

  • Latest Funding Round
    $8.3 M (USD), Series A

    Jul 14, 2017

  • Investors
    Matrix
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Qrativ

Qrativ has successfully raised a total of $8.3M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.3 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $8.3M
  • First Round

    (14 Jul 2017)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2017 Amount Series A - Qrativ Valuation

investors
Matrix

Investors in Qrativ

Qrativ has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Matrix.

All
Venture Fund
Investor Description Founded Year Domain Location
Matrix
Early-stage ventures are funded by the investment firm.
Founded Year Domain Location

Investments & Acquisitions by Qrativ

Investments

Financial Statements - Qrativ

Qrativ Comparisons

+
Add Comparison
Available on Premium

Competitors of Qrativ

Qrativ operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Causaly, ScienceIO, Collaborative Drug Discovery, BioSymetrics and Citelighter, among others.

Company Name Domain Founded year HQ Location Description
Causaly
domain founded_year HQ Location
AI-based data-mining tools for scientific evidence discovery are provided.
ScienceIO
domain founded_year HQ Location
Provider of AI solutions transforming medical text into enriched healthcare data
Collaborative Drug Discovery
domain founded_year HQ Location
Biological and chemical data are managed securely in a database.
BioSymetrics
domain founded_year HQ Location
Provider of a cognitive computing-based biomedical intelligence platform
Citelighter
domain founded_year HQ Location
Digital writing solution for K-20 students

Latest news on Qrativ

Frequently Asked Questions about Qrativ

Qrativ was founded in 2017.

Qrativ is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Murali Aravamudan is the current CEO of Qrativ. They have also founded this company.

Qrativ is a funded company, having raised a total of $8.3M across 1 funding round to date. The company's 1st funding round was a Series A of $8.3M, raised on Jul 14, 2017.

Qrative is a joint venture formed by Mayo Clinic nference to identify treatments for rare diseases using drug purposing approach. The company has developed a propriety drug purposing platform, Darwin.ai, leverages proprietary data from Mayo Clinics (EHRs, prescription diagnosis data, patient-treatment omics) and nferences knowledge synthesis AI platform (data extracted from PubMed, Clinical Trials, etc). The company claims that the drug developers can use its platform to identify uses for their molecules at an early phase of development. The company has got 8.3 million funding from Matrix Capital Management, Matrix Partners, and the Mayo Clinic.

Qrativ's top competitors include Causaly, ScienceIO and BioSymetrics.

Qrativ has 1 investor. Key investors include Matrix.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available